TIL

5.2305.77%
NW

Neil W. Gibson

Independent Director

Dr. Neil W. Gibson, Ph.D., is Member of Scientific Advisory Board of Aimed Bio Inc. Dr. Gibson serves as Member of Scientific Advisory Board at OncoMyx Therapeutics, Inc. He serves as Director of Causeway Therapeutics Ltd. He serves as a Non-Employee Director of Instil Bio Inc. since June 2020 and as lead independent director since March 2021. He served as Director at Cullinan Mica Corp. from 2020 until 2022. He served as the President's Fellow of Regulus Therapeutics Inc from June 2015 to June 30, 2015 and served as its Chief Scientific Officer since April 18, 2011 to 2015. Dr. Gibson served as the Chief Scientific Officer of OSI Pharmaceuticals Inc. since September 20, 2005. Dr. Gibson served as Vice President of Research at OSI Pharmaceuticals Inc. from October 2002 to September 2005 and served as its Vice President, U.S. Research from August 2001 to October 2002 and Senior Director of Cancer Discovery from January 2001 to August 2001. Dr. Neil W. Gibson served as Vice President of OSI Pharmaceuticals Inc. since September 2005. Dr. Gibson has many years of pharmaceutical drug development experience, including the direction of strategy for oncology discovery efforts at Pfizer. Dr. Gibson served as Director of Cancer Research at Bayer Corporation in West Haven, Connecticut from May 1997 to January 2001. Dr. Gibson served as a Senior Research Investigator in Pfizer Inc.'s cancer discovery group. He was President of the British Pharmaceutical Students Association. Dr. Gibson enjoyed a successful academic career in cancer research, holding various positions at the University of Southern California, the AMC Cancer Research Center in Denver, CO, Fox Chase Cancer Center in Philadelphia, Pennsylvania and the National Cancer Institute in Bethesda, Maryland. Dr. Gibson serves as an Independent Director of TCR2 Therapeutics Inc. since February 2018 and Causeway Therapeutics since 2017 and previously served on the Board of Cytosen Therapeutics from 2016 to 2019. He serves as Independent Director of Shattuck Labs, Inc. since November 2016. Since 2016, he has served as Senior Vice President to COI Pharmaceuticals, Inc and Avalon Ventures. From 2015 to 2016, Dr. Gibson served as Senior Vice President and Chief Development Officer to BioAlta LLC and from 2013 to 2016, he served as Chair of Scripps Advance LLC. He was President and Chief Executive Officer of PDI Therapeutics. From 2007 to 2011, he was Chief Scientific Officer of Pfizer Oncology based in La Jolla, CA. Dr. Gibson serves on the National Cancer Institute's Experimental Therapeutics Study Section and is actively involved with the American Association of Cancer Research. Previously, Dr. Gibson served as President and Chief Executive Officer of Adanate from 2017 to November 2021 and President and Chief Executive Officer of PDI Therapeutics from 2017 to June 2020, both COI Pharmaceuticals, Inc. Dr. Gibson has held various senior positions within the biotechnology and pharmaceutical industry, including President and Chief Executive Officer of PDI Therapeutics from 2017 to 2020, Senior Vice President of BioAtla, Inc. from 2015 to 2016 and Chief Scientific Officer of Regulus Therapeutics from 2011 to 2015. Dr. Gibson received his Ph.D. in cancer pharmacology from the University of Aston in Birmingham, UK in 1982 and his B.Sc. in Pharmacy from the University of Strathclyde in Glasgow, Scotland.

Positions